Search

Search Constraints

You searched for: Author/Creator Xu, Chong-Rui

Search Results

1. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. (December 2017)

2. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival. (January 2023)

3. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). (March 2019)

4. Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. (June 2021)

5. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. (2nd November 2017)

7. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. Issue 1 (December 2016)

8. Symptom and Quality of Life Improvement in LUX-Lung 6. Issue 6 (June 2015)

9. Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer. Issue 6 (June 2015)